Drug intelligence / Profile preview

Novel Compound 9

Development stage: Preclinical
Lead developer: Eluciderm
Modality: Small Molecules
Administration: Topical

Overview

Novel Compound 9 is a preclinical-stage small molecule therapeutic being developed by Eluciderm for the topical treatment of acne vulgaris. As part of Eluciderm's proprietary platform, the compound is designed to modulate the Wnt signaling pathway to activate the body's natural regenerative mechanisms. While specific molecular targets within the Wnt pathway have not been publicly disclosed for this particular candidate, the drug is intended for topical application to address the underlying pathology of acne. It is currently undergoing preclinical evaluation to support further clinical development.

Beyond the preview

Go deeper on Novel Compound 9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel Compound 9.

Explore the full profile